[StephN]

Thank you, Jade, for posting this one.

This is the most important part of the article to me:

With certain types of cancer, "one-size-fits-all therapy isn't going to work," said Slamon, explaining that researchers have been working to create different classes of drugs that home in on cancer cells only, leaving healthy cells alone.
"We began to look for specific therapies designed to fix what is broken instead of throwing in a bomb hoping to kill more bad than good cells," he said. "So we would target what's broken in the malignant cells. And since the normal cells don't have what's broken, they would be spared.
"And that is the whole idea of designer therapy or sharp-shooter drugs."
CFI-400945 is a new class among these designer drugs, designed to take aim at an enzyme called PLK4, which plays a critical role in cell division, especially in cancer cells.
Cells in some "genomically unstable" cancers can have scores more chromosomes than the 46 present in normal cells, and these malignant cells rely on PLK4 to be able to continue to proliferate out of control.
"So we target (the enzyme) to make sure that those cancer cells that have many chromosomes and aren't genomically stable cannot survive," said Mak.
If given FDA go-ahead for a patient trial, researchers will begin by administering the drug in about 30 volunteers with breast or ovarian cancer to see how strong a dose they can tolerate without it becoming dangerously toxic.

This is a NEW approach and I know that there are some "Sheilas" and "Chrisys" out there who are lining up to get this possible new drug.